CAJ | 학술논문

目的探讨我院在中晚期直肠癌术中植入缓释氟尿嘧啶(中人氟安)治疗效果及可行性。方法分析我院2010年1月~2011年11月188例中晚期直肠癌临床资料。分为两组A治疗组,术中使用植入缓释氟尿嘧啶96例；B对照组,不植入缓释氟尿嘧啶92例。术后4w均采用静脉化疗,并作随访观察。结果对照组术后因感染出现2例吻合口漏,4例肠梗阻,6例发热,经治疗后好转。治疗组术后未发生吻合口漏、切口感染和盆腔积液及肠梗阻等不良反应,有8例出现发热,6例出现白细胞降低,经对症治疗后好转。两组统计学比较P>0.05。术后12、24个月随访或检查发现治疗组局部复发率均低于对照组(P<0.05),两组远处转移和死亡率比较无统计学意义(P>0.05)。结论术中植入缓释氟尿嘧啶安全、可行,可降低中晚期直肠癌术后复发率及提高术后生存率。
목적탐토아원재중만기직장암술중식입완석불뇨밀정(중인불안)치료효과급가행성。방법분석아원2010년1월~2011년11월188례중만기직장암림상자료。분위량조A치료조,술중사용식입완석불뇨밀정96례；B대조조,불식입완석불뇨밀정92례。술후4w균채용정맥화료,병작수방관찰。결과대조조술후인감염출현2례문합구루,4례장경조,6례발열,경치료후호전。치료조술후미발생문합구루、절구감염화분강적액급장경조등불량반응,유8례출현발열,6례출현백세포강저,경대증치료후호전。량조통계학비교P>0.05。술후12、24개월수방혹검사발현치료조국부복발솔균저우대조조(P<0.05),량조원처전이화사망솔비교무통계학의의(P>0.05)。결론술중식입완석불뇨밀정안전、가행,가강저중만기직장암술후복발솔급제고술후생존솔。
Objective To assess the safety and ef ect of intraperitoneal chemotherapy with sustained-release-fluorouracil for patients with advanced colorectal cancer Application;Methods A treatment group were divided into two groups, intraoperative use of fluorouracil sustained release implant 96 cases; B in the control group, 92 cases without implantation of fluorouracil. 4 weeks postoperative intravenous chemotherapy, and for fol ow-up observation.Results The control group were due to infection appear two cases of anastomotic leakage, four cases of intestinal obstruction, six cases of fever, improved after treatment. Anastomotic leakage did not occur after the treatment group, wound infections and pelvic fluid and intestinal obstruction and other adverse reactions, there are eight cases of fever, 6 cases leukopenia after symptomatic treatment improved. Comparison of the two groups was statistical y >0.05. 12 and 24 months fol ow-up after surgery or examination revealed local recurrence rate of the treatment group than the control group ( <0. 05), distant metastasis and mortality in the two groups was not significant ( >0.05).Conclusion Fluorouracil sustained release implant surgery is safe and feasible, can reduce the recurrence rate in advanced colorectal cancer and improve survival rates, with some clinical value.